Lenalidomide for second-line treatment of advanced hepatocellular cancer (HCC): A Brown University Oncology Group phase II study.

被引：0
|
作者：
Safran, Howard
Charpentier, Kevin
Kaubisch, Andreas
Dubel, Gregory
Perez, Kimberly
Faricy-Anderson, Katherine E.
Miner, Thomas J.
Victor, Joel
Taber, Angela Marie
Bakalarski, Pamela
Wingate, Patti
Mantripragada, Kalyan C.
Luppe, Denise
Rosati, Kayla
Espat, Joseph
Isdale, Debora
Eng, Yoko
Martel, Diane
Berz, David
Wands, Jack
机构：
[1] Brown Univ, Oncol Grp, Providence, RI 02912 USA
[2] Montefiore Med Ctr, Bronx, NY 10467 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4098
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer A Brown University Oncology Group Phase II Study
    Safran, Howard
    Charpentier, Kevin P.
    Kaubisch, Andreas
    Mantripragada, Kalyan
    Dubel, Gregory
    Perez, Kimberly
    Faricy-Anderson, Katherine
    Miner, Thomas
    Eng, Yoko
    Victor, Joel
    Plette, Angela
    Espat, Joseph
    Bakalarski, Pamela
    Wingate, Patti
    Berz, David
    Luppe, Denise
    Martel, Diane
    Rosati, Kayla
    Aparo, Santiago
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (01): : 1 - 4
  • [2] Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
    Shao, Y-Y.
    Chen, B-B.
    Lin, Z-Z.
    Hsu, C-H.
    Wang, M-J.
    Cheng, A-L.
    Hsu, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Yung-Jue Bang
    Yoon-Koo Kang
    Won K. Kang
    Narikazu Boku
    Hyun C. Chung
    Jen-Shi Chen
    Toshihiko Doi
    Yan Sun
    Lin Shen
    Shukui Qin
    Wai-Tong Ng
    Jennifer M. Tursi
    Maria J. Lechuga
    Dongrui Ray Lu
    Ana Ruiz-Garcia
    Alberto Sobrero
    Investigational New Drugs, 2011, 29 : 1449 - 1458
  • [4] Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group
    Katsaounis, Panagiotis
    Kotsakis, Athanasios
    Kentepozidis, Nikolaos
    Polyzos, Aris
    Bakogeorgos, Marios
    Koinis, Filippos
    Vamvakas, Lambros
    Vardakis, Nikolaos
    Kalbakis, Kostas
    Boukovinas, Ioannis
    Varthalitis, Ioannis I.
    Prinarakis, Efthimios
    Georgoulias, Vassilis
    Souglakos, John
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (01): : 65 - 70
  • [5] Folfiri as second-line treatment in advanced pancreatic cancer: A phase II study
    Giuliani, F.
    Mallamaci, R.
    Di Bisceglie, M.
    Galetta, D.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII158 - VII158
  • [6] Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Kang, Won K.
    Boku, Narikazu
    Chung, Hyun C.
    Chen, Jen-Shi
    Doi, Toshihiko
    Sun, Yan
    Shen, Lin
    Qin, Shukui
    Ng, Wai-Tong
    Tursi, Jennifer M.
    Lechuga, Maria J.
    Lu, Dongrui Ray
    Ruiz-Garcia, Ana
    Sobrero, Alberto
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1449 - 1458
  • [7] Gefitinib phase II study in second-line treatment of advanced esophageal cancer.
    Van Groeningen, C
    Richel, D
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 319S - 319S
  • [8] Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC)
    Chelis, Leonidas
    Deftereos, Savas
    Xenidis, Nikolaos
    Amarantidis, Kiriakos
    Hamalidou, Eleni Kyrillos
    Dimopoulos, Prokopios
    Michailidis, Prodromos
    Christakidis, Evagelos
    Mimidis, Kostantinos
    Pitsiava, Dimitra
    Karayiannakis, Anastasios
    Kakolyris, Stylianos
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P
    Dizon, Don S.
    Blessing, John A.
    McMeekin, D. Scott
    Sharma, Sudarshan K.
    DiSilvestro, Paul
    Alvarez, Ronald D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3104 - 3108
  • [10] Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.
    Yi, J.
    Thongprasert, S.
    Doval, D.
    Lee, J.
    Cho, M. N.
    Park, S. H.
    Park, J. O.
    Park, Y. S.
    Kang, W. K.
    Lim, H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345